Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EBIT (2016 - 2025)

KalVista Pharmaceuticals' EBIT history spans 11 years, with the latest figure at -$55.0 million for Q2 2025.

  • For Q2 2025, EBIT fell 13.57% year-over-year to -$55.0 million; the TTM value through Apr 2025 reached -$193.5 million, down 41.95%, while the annual FY2025 figure was -$188.0 million, 33.86% down from the prior year.
  • EBIT for Q2 2025 was -$55.0 million at KalVista Pharmaceuticals, down from -$45.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$12.7 million in Q1 2021 and bottomed at -$55.0 million in Q2 2025.
  • The 4-year median for EBIT is -$37.0 million (2023), against an average of -$36.8 million.
  • The largest annual shift saw EBIT rose 0.53% in 2021 before it tumbled 54.01% in 2024.
  • A 4-year view of EBIT shows it stood at -$12.7 million in 2021, then plummeted by 135.02% to -$29.7 million in 2023, then tumbled by 54.01% to -$45.8 million in 2024, then fell by 20.12% to -$55.0 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's EBIT are -$55.0 million (Q2 2025), -$45.8 million (Q4 2024), and -$44.2 million (Q3 2024).